Akerna (NASDAQ: KERN) business intelligence has revealed the US’s top five cannabis sales days for 2021.
Akerna to capture marijuana consumption in its flash report
The unofficial marijuana consumption holiday, 420, was the most successful cannabis sales day in history. The top cannabis sales days raked in a total of $493 million in marijuana sales. Later this month, Akerna will issue its yearly Cannabis Industry Year-End Review report, which will include further data, research, and industry information. You can subscribe to get it by filling out the form below.
Akerna’s MJ Freeway subsidiary gathers buying patterns in the cannabis sector for the Flash Report. MJ Freeway offers businesses with the MJ Platform, an industry-leading platform for regulatory compliance technology, from seed to sale to self. As a result, business intelligence from Akerna’s family of firms, such as Leaf Data Systems, Ample Organics, Solo Sciences, Viridian Sciences, 365 Cannabis, and Trellis, may be included in some instances of the flash report.
420 holiday reported the highest cannabis sales in 2021
The 420 holiday, which took place on April 20, 2021, generated $111.8 million in sales, while the Friday before labor day on September 3, 2021, the Company generated $90.1 million in cannabis sales. Black Friday on November 26, 2021, there were $99 million in sales with Green Wednesday, which was on November 24, 2021, racking sales of $98.2 million. On the Thursday before Christmas, sales were $94 million.
Business Intelligence Architect at Akerna James Ahrendt said, “When comparing the top sales day of 2021 to the top sales day of 2020, 2021 saw a 25% increase in sales. Last year’s top sales day – December 31, 2020 – wouldn’t have even made it on the top five chart in 2021.”
Akerna CEO Jessica Billingsley said, “We’ve diligently been tracking legal cannabis sales for over a decade and have seen constant growth each year, even amid the ongoing pandemic. Whether people are turning towards cannabis to celebrate holidays, for its countless medical benefits, or as an alternative to other substances, it’s clear that Americans are increasingly purchasing cannabis each year.”
Orchid Ventures Inc. (OTCMKTS: ORVRF) Signs Agreement To Seek Approval For Disposable Vaporizer Device in Europe
Orchid Ventures Inc. (OTCMKTS: ORVRF) has announced the signing of an exclusive agreement with Germany-based pharmaceutical firm Eurox Pharma GmbH.
PurTec, Eurox, and JWEI are seeking approval for a disposable vaporizer device
PurTec, Eurox, and JWEI, Orchid Ventures’ OEM supplier and partner, shall submit one of the premium disposable vaporizer devices from PurTec for Medical Device Approval in Germany under the agreement terms. To establish the device’s safety and efficacy, all three firms will collaborate on many requirements as well as safety studies. Also, to expedite the clearance process, the firms have already started obtaining numerous certifications. Eurox will have exclusive sales and distribution rights to the PurTec disposable vaporizer device in the EU, the UK, and Brazil once the device is certified.
Interestingly the agreement marks the first project PurTec will undertake in Europe
Orchid Ventures founder, chairman, and CEO Corey Mangold states, “After months of planning and strategizing, we are pleased to announce our partnership with such an established group in Eurox. We’re thrilled to join forces with Eurox and to be submitting one of our most stringently tested vaping products for Medical Device Approval with German health authorities. Once the product is accepted, this will be a huge step forward in our ability to deliver one of the first vaping products to patients and consumers in Germany, along with several other European countries. We are confident that with the combined experience and expertise of Eurox and JWEI, we will succeed in getting approval and be among one of the first vaporizer products in-market and available to consumers throughout the EU.”
Partnership to expand Eurox’s portfolio
Eurox Pharma GmbH Co-CEO Bernhard Babel said, “We are excited about this partnership. We believe that PurTec and JEWI will be valuable, long term partners that can help us expand access to relevant and exciting new products that will compliment our portfolio and advance our growth trajectory. Our objective is to deliver with liquid vaping a controlled and consistent therapy form to patients with need for inhaling in Europe and beyond.”
Emerald Health Therapeutics Inc. (OTCMKTS: EMHTF) Signs Binding Agreement To Sell Patents And Related IP To FlowerPod
Emerald Health Therapeutics Inc. (OTCMKTS: EMHTF) has signed a binding term sheet to sell all patent and associated IP pertaining to its vaporizer cannabis puck concept to FlowerPod LLC for $1 million in cash plus a $0.5 million one-year interest-carrying secured promissory note.
Emerlad to finalize dela in Q1 2022
Emerald will return its ownership interest to FlowerPod LLC as part of the deal but will keep the $350,000 two-year interest-carrying promissory note it obtained from FlowerPod LLC on May 5, 2021. The deal is expected to finalize in late Q1 of 2022.
The company and HYTN Cannabis Inc. have also decided to wind down their strategic relationship, which was first disclosed on November 3, 2021, in a timely and cooperative manner. Emerald has equally taken measures to minimize its burn rate significantly.
Chair of Emerald’s Board Jim Heppell said, “As I mentioned at our AGM on December 30, 2021, since announcing on November 29, 2021, that Emerald was pivoting out of the cannabis industry and into pharmaceutical development, I have been very pleased with Emerald’s progress on negotiations to sell its cannabis industry assets for cash. The Board and management are looking forward to our meeting with Vantage Point later this week, where we will be focusing on prioritizing their shortlist of merger/acquisition candidates involved in pharmaceutical development.”
Emerald is exiting the medical and recreational cannabis market
Recently the company announced that it is exiting the medical and recreational cannabis business to pivot to pharmaceutical development. To further enhance its already solid capital position, Emerald seeks to sell its medical and recreational use cannabis businesses, as well as make major cost cutbacks to reduce its monthly net burn.
Emerald plans to optimize its financial position and pursue market opportunities in pharmaceutical research, an area in which the Emerald Board of Directors has extensive experience. Regulatory permission is required for any acquisitions or dispositions, and shareholder approval may be required as well. The company also announced the resignation of its CEO & President Riaz Bandali effective December 31, 2021.
Global Hemp Group Inc. (OTCMKTS: GBHPF) Finalizes Incorporation of its Mexican Subsidiary and Updates on R&D Division
Global Hemp Group Inc. (OTCMKTS: GBHPF) has offered an update regarding its research and development initiatives in Mexico. In addition, the company has finalized the incorporation of a subsidiary in Mexico.
Global Hemp Group receives recognition in Mexico
While this was a lengthy procedure that took the better part of the year to complete, GHG now has official recognition in Mexico. As a government-recognized company, the company can now explore its hemp license to cultivate and extract hemp material for primary use by the R&D Division and participate in more substantial collaborations throughout Mexico. In addition, the Mexican Senate is anticipated to pass hemp and cannabis legislation during the current parliamentary session, which began in September.
Also, the company is thrilled to disclose that it has hired a team of US and Mexican patent attorneys to finish the documentation required to file the R&D Division’s first patent. The patent covers a new process for creating a hemp-based composite substance that might be utilized as an alternative for Medium Density Fibreboard in the building industry.
GHG announced a Collaboration Agreement with the National Autonomous University of Mexico (Universidad Nacional Autonoma de Mexico – UNAM), one of the world’s premier Spanish-speaking institutions and Latin America’s most prestigious educational institution, on August 24, 2021. This relationship gives GHG access to the university’s cutting-edge laboratory equipment, and also UNAM’s research library, and the ability to connect with students and academics with diverse backgrounds. In addition, this has allowed the R&D Division to broaden its experimental and conceptual work.
Global Hemp Group cancels $2.3 million
Additionally, GHG has announced the cancellation of 2.3 million common shares in its capital and their return to treasury. The shares were initially issued in connection with GHG’s Scio Oregon hemp initiative. The company kept them in escrow until the project met certain financial benchmarks before being released to specific employees and consultants. However, the company has recently stopped its Oregon operations to create its Green Community in Hayden, Colorado, as the project did not meet these milestones.